124I-omburtamab

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug Name124I-omburtamab
Drug Alias Name124I-8H9124I-8H9-(B7-H3)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanRadiation-emitting products > Radioactive therapeutic agent +[6] 
Mechanisms of ActionIonising radiation emittersCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsDiffuse midline glioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer CenterY-Mabs Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesY-Mabs Therapeutics IncMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsDiffuse midline glioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A